Literature DB >> 2878009

The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.

R J Comi, P Gorden.   

Abstract

SMS 201-995 (SMS) is a long-acting analog of somatostatin. We studied the effect of SMS (50-100 micrograms, sc, every 8 h) on serum GH in five patients with acromegaly. Serum GH decreased significantly in four of the five patients 4 h after SMS treatment. In two of the four patients, this reduction was not sustained for 7 h, but sustained reduction to normal GH concentrations did occur in the two patients who had basal serum GH levels below 15 ng/ml. In the two patients whose responses were not sustained for 7 h, a higher dose of SMS did not cause sustained reduction in GH. SMS was well tolerated, except for one episode of elevated serum aminotransferase levels. These results indicate that SMS-induced reductions in serum GH in patients with acromegaly are often not sustained despite SMS administration every 8 h and indicate that the insufficient duration of effect may limit its therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2878009     DOI: 10.1210/jcem-64-1-37

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Medical management of growth hormone-secreting pituitary adenomas.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.

Authors:  R Candrina; G Giustina
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

3.  Somatostatin receptor scintigraphy in patients with pituitary adenoma.

Authors:  A Rieger; N G Rainov; C Elfrich; M Klaua; H Meyer; C Lautenschläger; W Burkert; T Mende
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

Review 4.  Somatostatin analogs in medical treatment of acromegaly.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

5.  Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.

Authors:  G Mehltretter; S Heinz; J Schopohl; K von Werder; O A Müller
Journal:  Klin Wochenschr       Date:  1991-01-22

Review 6.  Current status and future opportunities for controlling acromegaly.

Authors:  Shlomo Melmed; Mary Lee Vance; Ariel L Barkan; Bengt-Ake Bengtsson; David Kleinberg; Anne Klibanski; Peter J Trainer
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 7.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 8.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

9.  Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy.

Authors:  G Hildebrandt; J Zierski; G Csecsei; H W Mueller; H Stracke
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.